These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 27872953)
1. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953 [TBL] [Abstract][Full Text] [Related]
2. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295 [TBL] [Abstract][Full Text] [Related]
3. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023 [TBL] [Abstract][Full Text] [Related]
5. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048 [TBL] [Abstract][Full Text] [Related]
6. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863 [TBL] [Abstract][Full Text] [Related]
7. A phase I study of volasertib combined with afatinib, in advanced solid tumors. Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473 [TBL] [Abstract][Full Text] [Related]
8. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063 [TBL] [Abstract][Full Text] [Related]
9. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334 [TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Marshall J; Shapiro GI; Uttenreuther-Fischer M; Ould-Kaci M; Stopfer P; Gordon MS Future Oncol; 2013 Feb; 9(2):271-81. PubMed ID: 23414476 [TBL] [Abstract][Full Text] [Related]
12. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464 [TBL] [Abstract][Full Text] [Related]
13. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Gordon MS; Mendelson DS; Gross M; Uttenreuther-Fischer M; Ould-Kaci M; Zhao Y; Stopfer P; Agus DB Invest New Drugs; 2013 Apr; 31(2):409-16. PubMed ID: 23242861 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Bahleda R; Hollebecque A; Varga A; Gazzah A; Massard C; Deutsch E; Amellal N; Farace F; Ould-Kaci M; Roux F; Marzin K; Soria JC Br J Cancer; 2015 Nov; 113(10):1413-20. PubMed ID: 26512876 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596 [TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837 [TBL] [Abstract][Full Text] [Related]
17. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378 [TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308 [TBL] [Abstract][Full Text] [Related]
19. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Marshall J; Hwang J; Eskens FA; Burger H; Malik S; Uttenreuther-Fischer M; Stopfer P; Ould-Kaci M; Cohen RB; Lewis NL Invest New Drugs; 2013 Apr; 31(2):399-408. PubMed ID: 23161335 [TBL] [Abstract][Full Text] [Related]
20. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]